The medication is commonly used to provide supportive hormonal assistance, contributing to symptomatic relief and benefits relevant to long-term management in contexts of estrogen deficiency. This medication is commonly used in the domain of Hormone Replacement Therapy.

Прогинова is applied across domains where additional symptomatic support is needed, primarily for managing menopausal complaints (climacteric symptoms) and for long-term support against bone density decline.

Relief of Systemic Symptoms

This therapy is applied in conditions marked by heightened symptoms of systemic imbalance, generally assisting with symptoms that interfere with daily functioning, such as disruptive hot flushes and persistent sweating. This supportive action may assist with easing the overall symptom load during symptomatic phases.

Support for Urogenital Health

Прогинова may assist with addressing specific, localized symptoms related to inflammatory or irritative states, such as chronic vaginal dryness and burning. The therapy contributes to improved comfort and supports functional stability in localized urogenital health.

---

Quick Fact: Relief for Systemic Imbalance

Прогинова assists with managing symptom clusters that create noticeable physiological strain, specifically those related to systemic imbalance (vasomotor symptoms) and localized inflammatory or irritative states (urogenital atrophy). It supports a long-term therapeutic benefit by assisting with supporting skeletal stability in patients at risk of future fractures.

Who Can and Cannot Use Прогинова?

The eligibility for Прогинова (Estradiol Valerate) is strictly determined by official regulatory labeling, which outlines mandatory exclusions and conditional use requirements. The medicine is indicated primarily for postmenopausal women.

Absolute Contraindications (Must Not Use)

Use is strictly prohibited for specific patient populations, including:

• A known, past, or suspected history of breast cancer or other estrogen-dependent malignant tumors.
• A history of or active venous thromboembolism (VTE) or arterial thromboembolic disease (e.g., stroke, myocardial infarction).
• Acute liver disease or unresolved liver function abnormalities.
• Undiagnosed genital bleeding.
• Known hypersensitivity to the active substance.

Physiological and Age Restrictions

The medicine is contraindicated during pregnancy and breastfeeding. It is not indicated for the pediatric population (under 18 years) as its safety and efficacy have not been established in children. Close medical supervision is required for conditional use in patients with pre-existing conditions such as diabetes mellitus, hypertension, endometriosis, or uterine fibroids.

Interactions with Other Medicines and Products

Official regulatory documentation identifies several categories of medicinal products that may interact with estrogens like estradiol valerate, primarily through effects on the drug's metabolism.

Metabolism-Related Interactions

Interacting Product Category	Effect on Estradiol Plasma Levels	Resulting Constraint
CYP3A4 Enzyme Inducers (e.g., phenobarbital, phenytoin, rifampicin, carbamazepine, St. John's Wort)	Reduced (Increased metabolism)	May lead to decreased therapeutic effect; requires clinical monitoring and potential regimen adjustment.
CYP3A4 Enzyme Inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice)	Increased (Decreased metabolism)	May increase the risk of side effects; requires careful observation.

---

Pharmacodynamic and Other Interactions

The product may also affect the plasma concentration of other concurrently administered drugs. It has been documented to interfere with drugs whose metabolism or action is affected by estrogens, such as oral anticoagulants (like warfarin), lamotrigine, cyclosporine, and glucocorticoids. Specifically, estrogens may reduce the effect of oral anticoagulants, necessitating close and frequent monitoring of coagulation tests (e.g., INR) and possible dose modification of the anticoagulant. Furthermore, use with drugs such as lamotrigine may lead to reduced efficacy of the co-administered drug. The interaction profile highlights the need for a comprehensive review of all concurrent medicinal products to manage potential clinical consequences.

How Прогинова Works

Progynova contains estradiol valerate, a prodrug that undergoes rapid hydrolysis after administration to release estradiol (17beta-estradiol), the primary active natural human estrogen. Its mechanism centers on engaging the body's estrogen receptor system to induce a biological response within target tissues.

---

Estrogen Receptor Agonism

Estradiol functions as a ligand for nuclear estrogen receptors ( ERalpha and ERbeta) distributed across various cell types, including those in bone, brain, and urogenital tissue. Ligand binding initiates receptor dimerization and translocation to the nucleus, where the complex binds to estrogen response elements (EREs) on DNA. This engagement modulates specific gene transcription, leading to the altered synthesis of proteins and subsequent intracellular and physiological adjustments.

---

Skeletal Pathway Modulation

In bone tissue, this activation influences the pathways regulating bone turnover. Estradiol modulates the activity of bone cells (osteoclasts and osteoblasts), specifically suppressing signaling mediators that govern bone resorption rate. This mechanistic effect shifts the balance toward bone mineral retention at the cellular level.

---

Neuroendocrine Signaling

In the central nervous system, estradiol influences key neuroendocrine pathways, including the hypothalamic-pituitary axis and thermoregulatory centers. It modulates the expression and activity of various neurotransmitters, thereby influencing autonomic signaling and central feedback loops.

How to Use Progynova (Estradiol Valerate)

Progynova (estradiol valerate) tablets are administered orally as a form of estrogen-only hormone replacement therapy (HRT). The standard regimen involves taking one tablet once daily. The medication is available in two approved strengths: 1 mg and 2 mg per tablet, with the principle of using the lowest effective dose for the shortest duration of therapy.

---

Administration Protocol

The tablets are to be swallowed whole with liquid and may be taken with or without food. For consistency in the treatment pattern, administration should occur at approximately the same time each day. Treatment may follow a Continuous Regimen (daily intake with no break) or a Cyclical Regimen (21 days of intake followed by a 7-day tablet-free interval), depending on the specific prescribing strategy.

Special Conditions and Timing:

For patients with an intact uterus, the estrogen-only therapy is used in conjunction with a progestogen for at least 12 to 14 days of each 28-day cycle. If a dose is missed, it should be taken within 12 hours of the usual time; if the delay exceeds 12 hours, the dose is typically skipped to prevent overdosing, as an extended interruption may lead to breakthrough bleeding.

Age-Group Guidance:

Progynova is not indicated for use in children and adolescents, and no specific dose adjustment is typically indicated for elderly patients.

Research evidence / Overview of Studies for Прогинова

Evidence for Relief of Systemic Symptoms (Vasomotor)

Research examining the systemic symptoms of menopause, such as frequent hot flashes and night sweats, primarily relies on short-term Randomized Controlled Trials (RCTs), where research examined systemic estrogen therapy for outcomes related to the frequency and severity of hot flashes and night sweats in postmenopausal women. These studies were used in research exploring how symptoms change over time by tracking the perceived intensity of these acute or disruptive episodes, often using patient-reported outcomes describing perceived discomfort. Studies observed women experiencing conditions characterized by fluctuating or episodic manifestations of menopausal symptoms. Researchers monitored outcomes over the short study period, typically lasting a few months.

Studies reported measurements of VMS frequency and severity. Research examined systemic estrogen for these symptoms compared to an inactive substance (placebo). Findings describe patterns observed in the studies that were related to systemic estrogen administration. Research highlights changes measured during the study period, noting that trials also observed a placebo effect (changes reported in the control group) in these research contexts.

Evidence for Support for Urogenital Health

Research has explored how systemic estrogen administration was evaluated for outcomes linked to inflammatory or irritative states such as vaginal dryness, burning, and discomfort. These studies primarily involved postmenopausal women reporting conditions marked by functional limitations related to urogenital atrophy. The research examined changes in patient-reported experiences and specific objective measures, such as the Vaginal Maturation Index (VMI), which is a biomarker used in studies exploring localized tissue health.

Studies reported how symptoms evolved in the observed populations, with systemic therapy being observed in some studies to align with a measurable change in both patient-reported outcomes and objective measures like VMI. This evidence contributes to understanding symptom patterns in conditions where symptoms may vary in intensity.

Evidence for Prevention of Postmenopausal Bone Density Decline

Findings indicate that systemic estrogen therapy was studied for its association with the overall rate of bone mineral loss. The research base for bone health involves a combination of large-scale RCTs and long-term observational studies monitoring changes in Bone Mineral Density (BMD) and, critically, the incidence of fractures (such as hip and spine fractures). Research describes that the administration of estrogen was associated with measurements of BMD. For the key outcome of fracture incidence, long-term observational data and large trials were used to study the long-term impact on the incidence of these episodic or acute changes.

What is Still Uncertain About the Evidence for Прогинова

A key research limitation is the reliance on extrapolation for long-term safety and fracture-reduction data, which is often sourced from trials using different systemic oral estrogens rather than being based solely on dedicated, long-term studies of oral estradiol valerate. Furthermore, evidence quality varies across studies, and findings for some secondary endpoints, such as certain quality of life measures, remain uncertain across the body of evidence. Comparative evidence is lacking against some non-estrogen options for symptom relief.

Key Studies & References

1. Progynova (Estradiol valerate) Summary of Product Characteristics / Patient Information Leaflet (Monograph)
2. Management of menopausal symptoms: NICE guideline NG23 (General clinical evidence framework)
3. Estrogen Therapy (StatPearls) (Informing indications and urogenital atrophy context)

Common questions about Прогинова (FAQ)

Q: Does Progynova have a maximum duration of use or is it a permanent treatment?

A: Regulatory documents emphasize that Hormone Replacement Therapy (HRT) should be used for the shortest duration necessary and at the lowest effective dose. Official warnings explain that the risk of certain serious side effects, such as blood clots and specific cancers, increases the longer the medication is used, particularly with use beyond five years. Regulatory sources generally recommend that the ongoing need for therapy is determined through regular risk assessments with a healthcare provider.

---

Q: Which other drugs is it dangerous to take with Progynova?

A: Official product information highlights drug interactions that may change how Progynova works or how other medications work. Regulatory documents mention interactions involving medicines that are known to influence the CYP3A4 liver enzyme, such as certain anticonvulsants, antibiotics, and the herbal supplement St. John's Wort. Additionally, taking Progynova with drugs that require precise dose monitoring, such as oral anticoagulants (like warfarin), necessitates close observation by a clinician.

---

Q: What are the signs of a severe allergic reaction to Progynova?

A: Though allergic reactions (hypersensitivity) are uncommon, the product label notes the potential for rare, severe reactions. In the rare event of a severe allergic reaction (anaphylaxis or angioedema), symptoms observed may include sudden swelling of the face, tongue, or throat, or difficulty breathing.

---

Q: What does the "valerate" part in estradiol valerate mean or do?

A: In official pharmacological terms, the valerate compound is known as an 'ester' attached to the estradiol. This forms a 'prodrug,' which is a compound that must be metabolized by the body after administration. The valerate compound is rapidly broken down to release the active hormone, 17\beta-estradiol, which is the key component responsible for the therapeutic effect.

---

Q: Can I drink alcohol while I am on Progynova therapy?

A: Official health guidance generally advises caution regarding alcohol consumption during HRT. Heavy alcohol use may interfere with the body's natural processes, potentially leading to increased levels of estrogen in the bloodstream. Official health guidance recommends consulting a healthcare provider regarding specific alcohol consumption habits.

---

Q: Do I need to take Progynova with food?

A: No specific requirement for food is mentioned in the administration protocol. The regulatory information states that the tablets may be taken with or without food. For consistency in the treatment pattern, it is advised to swallow the tablet whole with a liquid and take it at approximately the same time each day.

---

Q: What is the difference between the 1 mg and 2 mg tablet strengths?

A: The primary difference lies in the amount of active ingredient (estradiol valerate) contained in each tablet. Regulatory guidance stresses that HRT should be prescribed using the lowest effective dose. The dose, whether 1 mg or 2 mg, is selected by a healthcare provider, consistent with the principle of using the lowest effective dose for the treatment of symptoms.

---

Q: Can I cut, chew, or crush the Progynova tablets?

A: Regulatory instructions state that the tablets must be swallowed whole with liquid. They are not formulated to be cut, chewed, or crushed, as this may interfere with how the medicine is absorbed by the body.

How to Store and Dispose of Progynova

Progynova (estradiol valerate) tablets must be stored according to specific regulatory requirements to maintain product stability and safety. The medicine must be kept out of the sight and reach of children as a mandatory safety precaution.

Storage Conditions

Progynova should be stored below a specific temperature limit, typically below 30 C (86 F), or below 25 C (77 F) depending on regional labeling. It is required to store the tablets in their original packaging (carton and blister strip) and keep them away from heat, moisture, and direct sunlight.

Disposal Instructions

Expired or unused Progynova must not be disposed of in household trash or flushed down the toilet/wastewater, as required by environmental protection guidelines. All remaining product must be returned to a pharmacist for proper disposal.